Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Chengqing Wu
Observed names:
Chengqing (Alan) Wu,
Wu, Chengqing (Alan)
Observed institution:
Celgene (United States)
OpenAlex ID:
A5076729973
A 2-in-1 adaptive design to seamlessly expand a selected dose from a phase 2 trial to a phase 3 trial for oncology drug development
2022
·
Pingye Zhang
, Xiaoyun Nicole Li
, et al.
·
Contemporary Clinical Trials
·
12
A variation of a 2-in-1 adaptive design to seamlessly expand a selected dose from a phase 2 trial to a phase 3 trial for oncology drug development
2023
·
Pingye Zhang
, Xiaoyun (Nicole) Li
, et al.
·
Contemporary Clinical Trials
·
6
Efficacy and time to next treatment following lenalidomide/rituximab (R2) or rituximab/placebo in patients with R/R indolent NHL (AUGMENT).
2019
·
John G. Gribben
, Koji Izutsu
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
4
Citation count:
18
H-index:
2
I10-index:
1
Year
Topic
Type
